FOUR new chemical entities (NCEs) were registered with the Therapeutic Goods Administration as prescription medicines during the month of Sep.
They are Empliciti (elotuzumab) from Bristol-Myers Squibb for multiple myeloma; Biogen's Zinbryta (daclizumab), a multiple sclerosis therapy; Idelvion (albutrepenonacog alfa) from CSL Behring for haemophilia treatment; and Ei Lilly's Talz (ixekizumab) for psoriasis.
Three products were registered for extensions of indications: Adcetris (brentuximab vedotin), Simponi (golimumab) and Alprolix (eftrenonacog alfa).
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Sep 16
